DIRS.INFO The most relevant business & tech news

☆ This pharma stock is set to surge 71% thanks to autoimmune disease treatment
▼ + stars: | 2024-10-03 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Oppenheimer thinks a key treatment for a range of autoimmune diseases can be a growth catalyst for Dianthus Therapeutics stock. The firm initiated coverage of the clinical stage biotechnology company with an outperform rating and a $48 per share price target in a Wednesday note. DNTH YTD mountain Dianthus Therapeutics stock. He estimates a more than $20 billion market for this treatment. Investors will be able to gain insight into the treatment's effectiveness in clinical data that will begin to be released in mid-2025, Allred said.

Persons: Oppenheimer, Trevor Allred, Allred, DNTH103 Organizations: Dianthus Therapeutics, Therapeutics, pharma

☆ Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
▼ + stars: | 2024-09-26 | by ( ) www.businessinsider.com time to read: +7 min

A woman who had life-changing results on a popular weight loss drug struggled to afford it for years. AdvertisementTara Rothenhoefer, a 49-year-old Florida resident, says her life changed when she joined a clinical trial for a promising new weight-loss medication. While regulated, these compounded drugs aren't FDA-approved, raising concerns from doctors about variations in quality. The grey market of weight-loss drugs is vast and complicated. In August, Eli Lilly halved the price of its weight-loss drug Zepbound through single-dose vials — a bid to lure customers back to brand-name drugs, analysts said.

Persons: —, Tara Rothenhoefer, Rothenhoefer, Eli Lilly, She's Organizations: Service, Novo Nordisk's, Research, FDA, Pharmaceutical Locations: Florida

☆ Sean ‘Diddy’ Combs wants to testify at his trial, lawyer says: ‘I don’t know that I can keep him off the stand’
▼ + stars: | 2024-09-26 | by ( Elizabeth Wagmeister | ) edition.cnn.com time to read: +4 min

CNN —Sean “Diddy” Combs wants to testify at his criminal trial for charges of sex trafficking and racketeering, according to his attorney. He is very eager to tell his story,” the embattled rap mogul’s attorney Marc Agnifilo said in an interview for a new TMZ documentary. When contacted by CNN, a representative for Combs declined to elaborate on Agnifilo’s comments or say whether Combs will, in fact, take the stand. Asked by TMZ about video of Combs, Agnifilo said that if Combs testifies, he would explain his actions in the video. And I’m not really sure what the baby oil has to do with anything,” Agnifilo said in his interview with TMZ.

Persons: Sean “ Diddy ” Combs, “, Marc Agnifilo, Combs, Cassie Ventura, Agnifilo, ” Agnifilo, Combs “, ”, Agnifilio, Kaitlan Collins, ” Combs, R, Kelly, “ Pharma Bro ” Martin Shkreli, Ghislaine Maxwell, Sam Bankman, Juan Orlando Hernandez Organizations: CNN, TMZ, Prosecutors, ” Prosecutors, Southern, of, Costco, Metropolitan Detention, “ Pharma, MDC Locations: Los Angeles, of New York, New York, Honduras

☆ Brett Favre reveals he's been diagnosed with Parkinson's disease
▼ + stars: | 2024-09-24 | by ( Geoff Weiss | ) www.businessinsider.com time to read: +1 min

Brett Favre said he's recently been diagnosed with Parkinson's disease. Prevacus and its investors, including Favre, have been tied up in a Mississippi welfare fraud case. Go to newsletter preferences Thanks for signing up! AdvertisementFormer NFL star quarterback Brett Favre revealed during a congressional hearing on Tuesday that he had "recently been diagnosed with Parkinson's" — a neurodegenerative disease. "I'm sure you'll understand, while it's too late for me because I've recently been diagnosed with Parkinson's, this is also a cause dear to my heart."

Persons: Brett Favre, he's, Favre, —, it's, I've Organizations: pharma, Service, NFL, Business Locations: Mississippi

Wegovy, the blockbuster weight loss treatment from Novo Nordisk , tops the list of drugs that could soon become part of the second round of price negotiations between manufacturers and Medicare. The Biden administration last month announced new negotiated prices for the first 10 Medicare Part D drugs selected for the talks. He also pushed back on Medicare price negotiations when asked about the potential selection of Wegovy and Ozempic, calling the talks "price-setting" that will have negative consequences for drug innovation. Medicare Part D doesn't cover weight loss treatments unless they are approved and prescribed for another health condition. We'll be following the next round of Medicare drug price negotiations closely, so stay tuned for our coverage.

Persons: Wegovy, Hollie Adams, Biden, it's, Novo, Lars Fruergaard Jørgensen, Lars Jorgensen, Ozempic, Piroschka Van De Wouw, Jørgensen, Semaglutide, We'll, Annika, annikakim.constantino Organizations: Novo Nordisk, Reuters, Specialty Pharmacy, Centers, Medicare, Medicaid Services, Health, Education, Labor, Capitol, CMS, Wall Street, GSK, Astellas Pharma, Epic Systems Locations: London, Britain, Novo, Washington , U.S

☆ ‘Greed, greed, greed’: Sanders demands Ozempic maker lower prices
▼ + stars: | 2024-09-24 | by ( Meg Tirrell | Tami Luhby | ) edition.cnn.com time to read: +7 min

“We are very committed to making sure that Americans have access at an affordable price point for our medicines,” Jorgensen replied. Similarly, Wegovy’s list price is $1,349 in the US, but it costs $186 in Denmark, $140 in Germany and $92 in the United Kingdom, he said. Tuesday’s hearing boiled down to a familiar argument over who is responsible for the US’s higher prices: drug companies that set starting – or “list” – prices or pharmacy benefit managers, the middlemen that negotiate discounts on those list prices in exchange for favorable insurance coverage and access. Jorgensen said Novo Nordisk pays back about 75% of its medicine sales in rebates, discounts and fees, so the net price it receives is far lower than the list price. “The broad totality is that less patients have access to our medicines when we lowered the price,” Jorgensen told Sen. Maggie Hassan, D-New Hampshire, after she pressed him to reduce list prices.

Persons: Sen, Bernie Sanders, ” Sanders, Lars Fruergaard Jorgensen, ” Jorgensen, “, Sanders, Jorgensen, it’s, Maggie Hassan, drugmakers, ”, PBMs, scot, ” Sen, Tim Kaine, Roger Marshall, Eli Lilly, Dr, Sanjay Gupta, Tammy Baldwin Organizations: CNN, Nordisk’s, US, Health, Education, Labor, Pensions, Yale, Novo Nordisk’s Ozempic, Novo Nordisk, Pharmaceutical Care Management Association, Nordisk, Novo Nordisk’s, Federal Trade Commission, CVS, Cigna’s, Republican, Wegovy’s, CNN Health, Medicare, Services Locations: United States, Danish, America, Canada, Denmark, Germany, United Kingdom, New Hampshire, Big, Virginia, Kansas, Novo, Wisconsin

☆ Stocks making the biggest moves midday: Micron, Tesla, Ulta, Intel and more
▼ + stars: | 2024-09-23 | by ( Pia Singh | In | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading: Micron Technology — Micron edged 2.7% higher after JPMorgan reiterated the stock as overweight ahead of the memory chipmaker's earnings, which are expected Wednesday after market close. Monday's gain put the stock on track for its biggest advance since Aug. 28, when it popped 9%. Ulta — The cosmetics stock lost more than 3% after a downgrade to hold from buy at TD Cowen. Biohaven — Shares surged 12% after the clinical-stage pharma company announced positive trial data for its drug treating spinocerebellar ataxia known as troriluzole. Intel — Shares of the struggling chipmaker climbed 2.4% after Bloomberg News reported on Sunday that Apollo Global Management proposed to make a multibillion-dollar investment in Intel.

Persons: Harlan Sur, General Motors, Bernstein, Cowen, troriluzole, Ciena, Jesse Pound, Alex Harring, Samantha Subin, Sean Conlon Organizations: Micron Technology, Micron, JPMorgan, Tesla, Barclays, U.S . Army, General, pharma, Intel —, Bloomberg, Apollo Global Management, Intel, CNBC, Qualcomm, Citi

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices. PBMs work with insurance companies to negotiate discounted prices from drug companies in exchange for including the drugs in their coverage. The drug was priced at $274 in 2017, as a result of the PBMs rebate system strategy, the FTC said. In July, Democratic and Republican lawmakers blamed executives from Caremark, Express Scripts and Optum Rx for sky-high prescription drug prices in the U.S. during an oversight committee hearing. The lawsuit also comes as states — most recently Vermont — have sued PBMs, alleging they drive up drug costs.

Persons: Cigna, Eli Lilly, Rahul Rao, It’s, Raja Krishnamoorthi, PBMs Organizations: Federal Trade Commission, FTC, CVS, Cigna's, Zinc Health, Ascent Health, Emisar Pharma Services, UnitedHealth, CVS Health, Novo Nordisk, Democratic, Republican, Caremark, New York Times, Republicans, ” Rep Locations: U.S, FTC’s, Vermont

☆ Morgan Stanley says this pharma stock can rally more than 60% thanks to its narcolepsy treatment
▼ + stars: | 2024-09-20 | by ( Pia Singh | In | ) www.cnbc.com time to read: +2 min

Centessa Pharmaceuticals could be at the forefront of a leading narcolepsy treatment that can send its shares soaring, according to Morgan Stanley. One of the company's drugs is ORX750 for the treatment of sleep-wake disorders, including narcolepsy type 1 and 2, or NT1 and NT2. Additionally, Centessa is developing ORX142 for the treatment of excessive daytime sleepiness, or EDS, in certain neurological, neurodegenerative and psychiatric disorders. The drug is designed to increase wakefulness, reduce cataplexy and potentially be a novel treatment for narcolepsy type 1. Given the firm's view of ORX750 as a now de-risked mechanism for treating narcolepsy, Hung modeled a higher peak market share for the treatment in NT1 by 2036.

Persons: Morgan Stanley, Jeffrey Hung, narcolepsy, Hung Organizations: Pharmaceuticals, IH, EDS Locations: NT1, NT2

☆ Pfizer is a bottoming stock that will pay you to wait for the comeback, says Carter Worth
▼ + stars: | 2024-09-20 | by ( Carter Braxton Worth | ) www.cnbc.com time to read: +2 min

Former pharmaceutical champion Pfizer (PFE) , down 52% from its December 2021 all-time high, is judged to be in the throes of a "bearish-to-bullish" Reversal. Pfizer, the laggard the past year: Is now... Pfizer, the leader the past month: By our work, PFE represents a compelling "value play". And with a 5.73% dividend yield, one "gets paid" to wait as the stock continues to bottom. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR.

Persons: Carter Braxton Worth Organizations: Pfizer, pharma, Pharmaceuticals Industry Group, CNBC, NBC UNIVERSAL

☆ J&J subsidiary files for bankruptcy to advance $8 billion talc settlement
▼ + stars: | 2024-09-20 | by ( ) edition.cnn.com time to read: +3 min

J&J’s Red River Talc unit made its filing in the U.S. Bankruptcy Court for the Southern District of Texas. J&J faces lawsuits from more than 62,000 claimants who alleged that its baby powder and other talc products were contaminated with asbestos and caused ovarian and other cancers. After being rebuffed twice by federal courts, New Brunswick New Jersey-based J&J is attempting again to end the litigation in a so-called “Texas two-step” bankruptcy. J&J said the Red River unit filed the bankruptcy case after it received support of about 83% of current claimants for the proposed bankruptcy plan. The goal is to use the proceeding to force all plaintiffs into one settlement, without requiring J&J itself to file for bankruptcy.

Persons: Reuters —, Johnson, J, Dietrich Knauth, Leigh Jones, Will Dunham, Sandra Maler, Shounak Dasgupta Organizations: Reuters, Johnson, Bankruptcy, Southern, Southern District of, Supreme, Purdue Locations: U.S, Southern District, Southern District of Texas, New Brunswick New Jersey, Texas, Bengaluru

☆ Mansion to misery: A glimpse inside the prison Sean ‘Diddy’ Combs now calls home
▼ + stars: | 2024-09-19 | by ( Artemis Moshtaghian | ) edition.cnn.com time to read: +5 min

CNN —Described as “disgusting” with “horrifying” conditions, the detention center music mogul Sean “Diddy” Combs now calls home is a far cry from the Miami and Los Angeles mansions he once lived in. A federal judge denied Combs bail Wednesday saying the bail proposal set forth by his defense attorneys was “insufficient” in addressing the court’s concerns. This after the Federal Bureau of Prisons shuttered its Manhattan complex shortly after multimillionaire financier and accused sex trafficker Jeffrey Epstein died by suicide in 2019. A month later, inmate Edwin Cordero died in a fight that broke out inside the prison. The incident prompted a Justice Department investigation assessing whether the Bureau of Prisons had “adequate contingency plans” to address inmate living conditions.

Persons: Sean “ Diddy ” Combs, he’s, ” Michael Cohen, Donald Trump, Cohen, R, Kelly, “, “ Pharma Bro ” Martin Shkreli, Ghislaine Maxwell, Sam Bankman, Ismael “ El, Ismael “ El Mayo ” Zambada Garcia, Combs, Judge Andrew Carter, Jeffrey Epstein, Emery Nelson, ” Nelson, ” Combs, Marc Agnifilo, “ He’s, ” Cohen, Combs ’, Uriel Whyte, Edwin Cordero Organizations: CNN, Miami, Metropolitan Detention Center, “ Pharma, Wap, Ismael “ El Mayo ”, Federal Bureau of Prisons, MDC, of Prisons, Urgent, MDC Brooklyn, Housing Unit, Prisons, New York Times, Department Locations: Los Angeles, “, New York, Brooklyn, Manhattan, New York City, M.D.C . Brooklyn

☆ GLP-1 pills are coming, and they could revolutionize weight-loss treatment
▼ + stars: | 2024-09-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

CNN —Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. At least a dozen similar experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing. Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience. The oral GLP-1 raceRight on the heels of oral semaglutide is a group of drugs led by Eli Lilly’s orforglipron, an oral medication that also targets GLP-1, which is a hormone implicated in insulin regulation, appetite and digestion. Drugmakers including Pfizer and Roche, as well as smaller companies like Structure Therapeutics, Terns Pharmaceuticals and Viking Therapeutics, also have oral weight-loss drugs in earlier stages of development, BMO research shows.

Persons: Jared Holz, ” Holz, ”, Jody Dushay, Dushay, ” Dushay, it’s, Rybelsus, Jorge Moreno, “, ” Moreno, Eli Lilly’s orforglipron, Lilly, Evan Seigerman, amycretin, who’ve, Dr, Sanjay Gupta, Holz, he’s, he’d Organizations: CNN, Harvard Medical School, Beth Israel Deaconess Medical, Novo Nordisk, US Food and Drug Administration, Yale School of Medicine, BMO Capital Markets, Pfizer, Roche, Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, BMO, Nordisk, European Association for, Diabetes, Inversago Pharma, CNN Health Locations: Danish, Novo

☆ Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
▼ + stars: | 2024-09-17 | by ( Kenneth Squire | ) www.cnbc.com time to read: +7 min

Bausch + Lomb parent company Bausch Health is spinning off the eye-care company with an upcoming IPO which will list on the New York Stock Exchange and TSX with the ticker symbol “BLCO”. This would greatly benefit BLCO stockholders, of which Bausch Health is the largest. As an 88% owner of BLCO, Bausch Health's value derived from such a sale would be $12.32 billion. Adding the value of the proceeds from BLCO sale, the Xifaxan cash flows and RemainCo yields a total value of $25.93 billion for Bausch Health. After subtracting 100% of the Bausch Health debt, that would yield an equity value of $10.49 billion or $28.19 per share.

Persons: Bausch, Scott Olson, Richard Mulligan, John Paulson, Brett Icahn, Steven Miller, Carl Icahn, BLCO, Goldman Sachs, Bausch Health's, Peers, InMode, Takeda, Gary Hu, Brent Saunders, Ken Squire Organizations: Bausch Health, New York Stock Exchange, TSX, U.S . Securities, Exchange, Financial Times, Cooper Companies, BLCO, Products, Takeda Pharmaceuticals, Ironwood Pharmaceuticals, Health, 13D Locations: CHICAGO , ILLINOIS, Chicago , Illinois, BLCO

☆ Here are Tuesday's biggest analyst calls: Nvidia, Palantir, Amazon, Shopify, Walmart, Microsoft, Palantir, Tesla & more
▼ + stars: | 2024-09-17 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Bank of America reiterates Amazon as buy Bank of America said it's sticking with its buy rating on Amazon following CEO Andy Jassy's letter to employees on Monday. Bank of America adds Palantir to the US1 list Bank of America added the stock to its top picks list. Bank of America reinstates Carvana as buy Bank of America resumed coverage of Carvana and upgraded it to buy saying it sees accelerating growth. Bank of America upgrades Hewlett Packard Enterprise to buy from neutral Bank of America said shares of the company are "attractive." Bank of America upgrades GE Vernova to buy from neutral Bank of America said it sees a "power surge" for the stock.

Persons: Oppenheimer, Andy Jassy's, Andy Jassy, Bernstein, Tesla, underperform Bernstein, Redburn, LSCC, Ford Tamer, Mizuho, DELL, Morgan Stanley, Virgin, Jefferies, it's bullish, JEF, ARMK, Baird, BTIG, " Jefferies, SolarEdge Organizations: Nvidia, " Bank of America, Bank of America, Semiconductor, Stifel, Board, Dell, JPMorgan, ViaSat, United Airlines, Viasat, IFC, Virgin Galactic, Virgin, Citi, UBS, APP, RBC, Baird Conference, Burger, Walmart, Technologies, Healthcare, Barclays, D, WEC, Hewlett Packard Enterprise, of America, Hewlett, Packard Enterprise, GE, Gas Power Services Locations: Europe

☆ How I'm approaching the stock market after its wild reversal to start September
▼ + stars: | 2024-09-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +7 min

The week before, Broadcom had allegedly disappointed, causing Nvidia , the inevitable key to this market, to continue its descent. Which brings me back to the initial concept of the big declining week followed by the big advancing week. A good week for Kamala Harris turns out to be a big week for Nextracker — and that's really it for now. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.

Persons: Larry Ellison, Ellison, Cerner, Ellison's, Eaton, Jensen, Bing, Microsoft's Bing, underinvesting, Huang, Blackwell, Dupont, Kamala Harris, Nextracker, Jim Cramer's, Jim Cramer, Jim, Justin Sullivan Organizations: Nasdaq, Federal, Broadcom, Nvidia, Oracle, Marvell, Meta, Microsoft, Google, mightily, Street, Fed, Dreamforce, downer, Adobe, JPMorgan, Healthcare, pharma, Jim Cramer's Charitable, CNBC Locations: Silicon Valley, San Francisco

☆ Morgan Stanley analysts give their favorite stocks to own for the next 12 months
▼ + stars: | 2024-09-13 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

From e-commerce firm Amazon to pharmaceutical giant Eli Lilly , Morgan Stanley's top stocks to own for the next 12 months spans a wide array of sectors. The majority of Morgan Stanley's picks are tilted toward growth, with 67% of the picks meeting that classification. Here's a look at some of the stocks that Morgan Stanley says are worth owning over the next year. Amazon stock has added 23% in 2024. LLY YTD mountain Eli Lilly stock.

Persons: Eli Lilly, Morgan, Morgan Stanley's, Morgan Stanley, Brian Nowak's, Nowak, Terence Flynn's, Eli Lilly's, LLY, Flynn Organizations: Nasdaq, Dow Jones, Amazon, Pharma

The hotly anticipated results are in from a landmark pair of major clinical trials of a long-acting, injectable HIV-prevention drug that only requires dosing every six months. The pharma giant has already secured approval for the injectable drug in treating highly drug-resistant HIV. Given the clear statistical superiority of lenacapavir over Truvada, the trial’s blinded phase will now be ended several months early. When taken as prescribed, Truvada is over 99% effective at preventing HIV; Descovy is comparably effective. This chorus is sure to get louder now that lenacapavir is officially highly effective at protecting gay and bisexual men and trans people as well.

Persons: lenacapavir, ”, Jared Baeten, “, ” Jen Kates, ” Gilead, Gilead, Truvada, ViiV Healthcare’s, Amy Killelea, Jirair Ratevosian, Hansel Tookes, ” Tookes, Dr, Boghuma, “ lenacapavir, Tim Horn Organizations: Gilead Sciences, pharma, NBC, Food and Drug Administration, Disease Control, PrEP, Yale School of Nursing, University of Miami Miller School of Medicine, NBC News, Southern, Affordable, CDC, Emory University Locations: Gilead, United States, ”, U.S, Australia, United Kingdom, Arlington , Virginia, America, South Africa, Thailand, Truvada, Atlanta, Saharan Africa

☆ The current market is 'directionless,' one CIO says, naming 6 stocks he likes right now
▼ + stars: | 2024-09-12 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +4 min

Defensive and dividend plays Alexander's strategy in playing the market right now is through defensive sectors and dividend players. As for dividend plays, Alexander is bullish on the utilities and telco sectors amid falling Treasury yields . Big pharma plays Alexander is also likes health-care and biotech players, especially big pharmaceutical companies producing products serving medical needs. Names he likes include AbbVie , AstraZeneca , Novartis and Johnson & Johnson . Johnson & Johnson, meanwhile, has been building out a "pipeline of drugs," Alexander added.

Persons: Ted Alexander, we've, we're, Alexander, it's, bullish, Durex, They've, Mead Johnson, Johnson Organizations: U.S, U.S . Federal, Sydney, Telecommunications, AT, Verizon, Frontier Communications, London Stock Exchange, Big pharma, AstraZeneca, Novartis, Johnson Locations: U.S ., South Dallas, U.S

☆ A promising cancer treatment is poised for explosive growth, says Redburn Atlantic. These stocks are on its buy list
▼ + stars: | 2024-09-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The latest weapon in the battle against cancer is showing promising results — and it's a growing opportunity for investors, according to Redburn Atlantic. To treat cancer, targeted radiopharmaceutical therapy directly goes after tumors with radiation by binding a radioactive particle to a targeting molecule. Delving into diagnostics There are also opportunities in the radiopharma diagnostics space, according to Redburn Atlantic. It has a "strong pipeline of radionuclides for both diagnosis and therapy," he said. "Lantheus benefits from its focus on this rapidly expanding market, with 78% of revenues from radiopharmaceuticals and related products," Ridley-Day added.

Persons: Ed Ridley, Eli Lilly, Myers, Ridley, Astra's, Lantheus Organizations: Big pharma, Novartis, Mariana Oncology, Biopharma, Myers Squibb, RayzeBio, AstraZeneca, Fusion Pharmaceuticals, GE Healthcare Technologies, Lantheus Holdings, GE Healthcare, GE Locations: Bristol, radiopharmaceuticals

Craig, the former mayor of Manchester, beat out Cinde Warmington, a former health care lobbyist and a member of the state’s Executive Council, in the Democratic primary. Tuesday’s winners will quickly move into a rapid eight-week general election campaign to replace Republican Gov. She held a wide lead in most polls of the GOP primary, allowing her to set her sights early on the general election. Meanwhile, Maggie Goodlander defeated Colin Van Ostern in a contentious and expensive Democratic primary in New Hampshire’s 2nd Congressional District, the AP projected. The winner of the primary will enter the general election as the favorite in the blue-leaning 2nd District.

Persons: Kelly Ayotte, Joyce Craig, Chuck Morse, Craig, Cinde, Chris Sununu, Amy Walter, ”, Warmington, Maggie Goodlander, Colin Van Ostern, Van Ostern, Goodlander, Jake Sullivan, Hillary Clinton, Annie Kuster, who’s Organizations: Associated Press, GOP, Democratic, Republican Gov, Purdue Pharma, Manchester, Congressional District, AP, Biden White House, Justice Department, Council, White House, District Locations: New Hampshire, Northeastern, Manchester, state’s, New Hampshire’s

☆ Mark Cuban is lauding Kamala Harris for joining him in his big fight to lower prescription drug prices
▼ + stars: | 2024-09-11 | by ( Kwan Wei Kevin Tan | ) www.businessinsider.com time to read: +1 min

Vice President Kamala Harris unveiled her policy platform on her campaign website on Sunday. Harris said she wants to lower drug prices "by taking on pharmacy middlemen." It appeared to cheer Mark Cuban, who's been taking on pharma companies with his own, Cost Plus Drugs. AdvertisementVice President Kamala Harris wants to lower drug prices, and billionaire investor Mark Cuban is all for it. The "Shark Tank" star then proceeded to quote part of Harris' policy position on drug prices in the same post.

Persons: Kamala Harris, Harris, Mark Cuban, who's, —, Joe Biden Organizations: pharma, Service, Democratic, Business

☆ What you need to know about Kamala Harris' 'opportunity economy'
▼ + stars: | 2024-09-11 | by ( Kwan Wei Kevin Tan | Joshua Nelken-Zitser | ) www.businessinsider.com time to read: +7 min

Read previewVice President Kamala Harris says she has a plan for America's middle class— building an "Opportunity Economy" to help them succeed. "Vice President Harris grew up in a middle class home as the daughter of a working mom. She believes that when the middle class is strong, America is strong," the Harris campaign wrote in a section titled "Build an Opportunity Economy and Lower Costs for Families." But just what exactly is Harris looking to do when she says she's going to build up the middle class through her "Opportunity Economy" agenda? During the debate, Harris accused Trump of only wanting to offer tax breaks to the richest people, while Trump countered by saying Harris lacked a detailed plan.

Persons: —, Kamala Harris, Harris, Donald Trump, she's, Biden, Trump, Alice Tecotzky, Goldman Sachs Organizations: Service, Business, Trump, American, Biden, Pharma, New York Times, Siena College Locations: America, North Carolina

☆ Stocks making the biggest moves midday: GameStop, Viking Therapeutics, Trump Media and more
▼ + stars: | 2024-09-11 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Trump Media & Technology — The stock fell more than 13% following Tuesday's debate between majority shareholder former President Donald Trump and Democratic Vice President Kamala Harris. Novartis — U.S.-listed shares of the Swiss pharma company slipped nearly 2% on the heels of Bank of America's downgrade to hold from buy. Crypto stocks — Crypto stocks were dragged downward after the price of bitcoin fell slightly overnight, as crypto traders considered central bank policy in Japan . Morgan Stanley — The bank stock lost 1% following a downgrade at Goldman Sachs to neutral from buy. Solar stocks — Solar stocks rose as a group after Vice President Kamala Harris's performance at Tuesday's debate raised confidence in a Democratic victory at the U.S. presidential election.

Persons: Donald Trump, Kamala Harris, Rentokil, it's, bitcoin, Morgan Stanley, Goldman Sachs, Goldman, Morgan, Warren Buffett's Berkshire Hathaway, Kamala Harris's, — CNBC's Sean Conlon, Michelle Fox, Alex Harring, Yun Li, Sarah Min, Samantha Subin Organizations: Trump Media & Technology, Democratic, Trump Media, Nasdaq, GameStop, Novartis — U.S, Swiss pharma, of, Therapeutics, JPMorgan, Viking Therapeutics, Goldman, Bank of America, U.S, Clean Energy, SolarEdge Technology, Sunnova Energy Locations: North America, Japan

New Hampshire voters will head to the polls Tuesday for a primary that will set up the matchup for one of just two governor’s races in presidential battleground states this year. In addition to North Carolina, New Hampshire is the only other swing state to hold a race for governor this election cycle. “I think that helps people in New Hampshire realize that Kelly Ayotte is a New Hampshire Republican, not a straight party loyalist,” Williams said. In New Hampshire, abortion is banned after fetal viability, or around the 24th week of pregnancy. “We’ve seen in the last few years that governors and state leadership sort of make or break it when it comes to protecting abortion rights,” Levy said.

Persons: Sen, Kelly Ayotte, Chuck Morse, Chris Sununu, Joyce Craig, Cinde Warmington, Amy Walter, Cook, Kamala Harris, Ayotte, Morse, Donald Trump, Trump, didn’t, hasn’t, Chuck Morse’s, he’s, Kelly, ”, Fergus Cullen, Cullen, Trumper, Sununu, Hillary Clinton, Joe Biden, “ She’s, Ryan Williams, “, ” Williams, “ Kelly, she’s, Maya Harvey, Chuck, ” Harvey, Craig, Jon Kiper, Warmington, Joyce Craig’s, Philip Stein, Kelly Ayotte’s, Joyce Craig's, ” Craig, Craig Brown, Craig “, “ It’s, Williams, They’ve, nodded, Neil Gorsuch, Gorsuch, Roe, Wade, Izzi Levy, “ We’ve, ” Levy, Dobbs, we’ve, Jason Osborne Organizations: New, Republican, GOP Gov, Democrats, Manchester, Hampshire, White, Democratic, GOP, New Hampshire Republicans, ” New, Republican Party, New Hampshire Republican, Purdue Pharma, Ayotte, Republicans, Hampshire Democrats, Trump, Democratic Governors Association Locations: New Hampshire, state’s, North Carolina , New Hampshire, Trump, Dover, ” New Hampshire, Manchester, Hampshire, New England, “ New Hampshire

Search resuls for: "Adienne Pharma

25 mentions found